As Eli Lilly outperforms Novo in market, it also replaces its rival in annual IDEA Innovation rankings
As Eli Lilly and Novo Nordisk continue to go in opposite directions in their diabetes and obesity market rivalry, so too have they changed positions in the annual IDEA Pharma Innovation Index. Lilly advanced from fourth place in 2024 to the top spot this year, supplanting 2024 champion Novo.
As Eli Lilly and Novo Nordisk continue to go in opposite directions in their diabetes and obesity market rivalry, so too have they changed positions in the annual IDEA Pharma Innovation Index. Lilly advanced from fourth place in 2024 to the top spot this year, supplanting 2024 champion Novo.
